



January 30, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Outcome of Board Meeting held on January 30, 2026

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. January 30, 2026, inter-alia considered and approved the following(s):

Financial Results

1. Un-audited (Consolidated & Standalone) Financial Results of the Company for the Quarter & Nine Months ended December 31, 2025.

Signed copy of the above Financial Results (Consolidated & Standalone) along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations, is enclosed herewith as **Annexure-A**.

Interim Dividend

2. Declaration of 3rd Interim Dividend of INR 3.5/- per equity share (@35% on a face value of INR 10/- each) for the financial year 2025-26. The Record Date for the purpose of payment of Interim Dividend shall be February 5, 2026.

The 3rd Interim Dividend will be credited within 30 days of its declaration.

Allotment of Equity Shares pursuant to Employee Stock Option Plan

3. Allotment of 4,000 Equity Shares under Employee Stock Option Plan 2010 of the Company.

Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to INR 1,67,55,50,200/- divided into 16,75,55,020 Equity Shares of INR 10/- each.

The Board Meeting commenced at 11:10 A.M. (IST) and concluded at 01:10 P.M. (IST).

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer
Encl.: As above

Deloitte Haskins & Sells LLP

Chartered Accountants
7th Floor Building 10
Tower B
DLF Cyber City Complex
DLF City Phase II
Gurugram-122 002
Haryana, India

Tel: +91 124 679 2000
Fax: +91 124 679 2012

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Dr. Lal PathLabs LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2025 ('the Statement'), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:
 - a) Dr. Lal PathLabs Limited, the Parent company
 - b) Paliwal Diagnostics Private Limited, a subsidiary company
 - c) Dr. Lal PathLabs Nepal Private Limited, a subsidiary company
 - d) Dr. Lal PathLabs Bangladesh Private Limited, a subsidiary company
 - e) Dr. Lal Ventures Private Limited, a subsidiary company
 - f) PathLabs Unifiers Private Limited, a subsidiary company
 - g) Dr. Lal PathLabs Kenya Private Limited, a subsidiary company (dissolved vide date of publication of gazette notification w.e.f. 13 September, 2024)
 - h) Suburban Diagnostics (India) Private Limited, a subsidiary company (voluntary liquidated on 11 February, 2025 with distribution of business undertaking to the Parent Company on a going concern basis)
 - i) Centrapath Labs Private Limited, a step-down subsidiary company
 - j) APRL PathLabs Private Limited, a step-down subsidiary company
 - k) Chanre Laboratory Private Limited, a step-down subsidiary company



5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited Consolidated Financial Results include the unaudited financial results and other unaudited financial information of two subsidiary companies which have not been reviewed by their auditors and have been approved and furnished to us by the Management, whose financial results reflect total revenue of Rupees 52.84 Million and Rupees 160.09 Million for the quarter and nine months ended December 31, 2025 respectively, total loss after tax of Rupees 5.59 Million and Rupees 8.56 Million for the quarter and nine months ended December 31, 2025 respectively, and total comprehensive loss of Rupees 5.36 Million and Rupees 6.91 Million for the quarter and nine months ended December 31, 2025, as considered in the Statement. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited financial results and other unaudited financial information certified by the Management. According to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the financial results certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)

Place: Gurugram
Date: January 30, 2026




RASHIM TANDON
Partner
Membership No: 95540
(UDIN: 26095540VVPBPM2359)

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC06538B

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December, 2025

(INR in million except as stated)

Particulars	3 months ended 31 December, 2025	Preceding 3 months ended 30 September, 2025	Corresponding 3 months ended in previous year 31 December, 2024	Year to date figures for the current period ended 31 December, 2025	Year to date figures for the previous period ended 31 December, 2024	Previous year ended 31 March, 2025
			(see note viii)			(see note viii)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income						
(a) Revenue from operations	6,598	7,306	5,957	20,602	18,588	24,614
(b) Other income	244	248	251	773	676	934
Total Income	6,842	7,554	6,218	21,375	19,264	25,548
2 Expenses						
(a) Cost of materials consumed	1,287	1,418	1,170	3,994	3,637	4,815
(b) Employee benefits expense	1,345	1,322	1,264	3,900	3,670	4,824
(c) Finance costs	72	48	53	167	173	223
(d) Depreciation and amortisation expense	421	405	355	1,172	1,055	1,419
(e) Fees to collection centers/channel partners	958	1,063	867	2,943	2,641	3,417
(f) Other expenses	1,215	1,262	1,126	3,718	3,375	4,603
Total expenses	5,298	5,518	4,835	15,984	14,551	19,301
3 Profit before exceptional items and tax	1,544	2,036	1,383	5,391	4,713	6,247
4 Exceptional items						
Impact of Labour Codes (see note x)	301	-	-	301	-	-
5 Profit before tax	1,243	2,036	1,383	5,090	4,713	6,247
6 Tax expense						
(a) Current tax	395	473	395	1,318	1,327	1,720
(b) Deferred tax	(66)	41	7	(4)	19	(395)
Total tax expense	329	514	402	1,314	1,346	1,325
7 Profit for the period (A)	914	1,522	981	3,776	3,367	4,922
8 Other comprehensive income/(loss)						
Items that will not be reclassified to profit or loss						
-Remeasurement of the defined benefit obligations	4	18	(1)	10	(13)	(49)
-Income tax in relation to the items that will not be reclassified to profit or loss	(1)	(5)	(1)	(3)	2	13
Items that may be reclassified to profit or loss	-	2	1	2	1	-
-Exchange differences on translation of foreign operations						
Total other comprehensive income/(loss) (B)	3	15	(1)	9	(10)	(36)
9 Total comprehensive income (A+B)	917	1,537	980	3,785	3,357	4,886
Profit for the period attributable to:						
Owners of the Company	905	1,506	967	3,735	3,323	4,871
Non-controlling interest	9	16	14	41	44	51
	914	1,522	981	3,776	3,367	4,922
Other comprehensive income/(loss) for the period attributable to:						
Owners of the Company	3	15	(1)	9	(10)	(36)
Non-controlling interest	-	-	-	-	-	-
	3	15	(1)	9	(10)	(36)
Total comprehensive income for the period attributable to:						
Owners of the Company	908	1,521	966	3,744	3,313	4,835
Non-controlling interest	9	16	14	41	44	51
	917	1,537	980	3,785	3,357	4,886
10 Paid-up equity share capital (Face value of INR 10 per share)	1,676	838	836	1,676	836	836
11 Other equity						20,891
12 Earnings per share (INR)						
(Face value of INR 10 per share)						
(not annualised for quarters) (see note ix)						
-Basic	5.42	9.03	5.80	22.38	19.96	29.24
-Diluted	5.41	9.01	5.79	22.35	19.92	29.20

Dr. Lal PathLabs Limited

Notes:

i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2025 and they have expressed an unmodified conclusion on the aforesaid results.

ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').

iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

iv. During the nine months ended 31 December 2025, the Parent Company has issued 183,775 equity shares of face value of INR 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").

v. The Board of Directors of the Parent Company have approved third interim dividend of INR 3.5 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2026.

The Board of Directors of the Parent Company had approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 which was paid on 17 November, 2025.

The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025.

The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025.

vi. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024.

vii. The Hon'ble Allahabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company. Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.

viii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis.

The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025.

ix. The shareholders of the Parent Company on December 07, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed December 19, 2025 as record date. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on December 22, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter September 30, 2025 and year ended March 31, 2025 and quarter/nine months ended December 31, 2024 have been restated to give effect to the allotment of the bonus shares.

x. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Consolidated Statement of Profit and Loss for the three months and nine months ended December 31, 2025. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.

xi. As at 31st December, 2025, the Parent company has the following subsidiaries:

Subsidiaries

Paliwal Diagnostics Private Limited

Dr. Lal PathLabs Nepal Private Limited

Dr. Lal Path Labs Bangladesh Private Limited

Dr. Lal Ventures Private Limited

PathLabs Unifiers Private Limited

Step-down subsidiaries

Centrapath Labs Private Limited


APRL PathLabs Private Limited

Chandre Laboratory Private Limited

JV/Associate Company- Nil

xii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram


Date: 30 January, 2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
Dr. Lal PathLabs LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)




RASHIM TANDON
Partner

Membership No: 95540)

UDIN: 26095540WCSHNS7521)

Place: Gurugram
Date: January 30, 2026

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December, 2025

(INR in million except as stated)

	Particulars	3 months ended 31 December, 2025	Preceding 3 months ended 30 September, 2025	Corresponding 3 months ended in previous year 31 December, 2024	Year to date figures for the current period ended 31 December, 2025	Year to date figures for the previous period ended 31 December, 2024	Previous year ended 31 March, 2025
		(Unaudited)	(Unaudited)	(See note vi)	(Unaudited)	(See note vi)	(See note vi)
1	Income						
	(a) Revenue from operations	6,321	6,996	5,692	19,724	17,744	23,516
	(b) Other income	266	228	313	757	863	1,115
	Total income	6,587	7,224	6,005	20,481	18,607	24,631
2	Expenses						
	(a) Cost of materials consumed	1,218	1,347	1,104	3,791	3,439	4,552
	(b) Employee benefits expense	1,274	1,251	1,204	3,783	3,490	4,584
	(c) Finance costs	70	46	51	161	167	215
	(d) Depreciation and amortisation expense	401	385	336	1,114	996	1,342
	(e) Fees to collection centers/channel partners	941	1,041	851	2,885	2,593	3,351
	(f) Other expenses	1,151	1,206	1,023	3,543	3,158	4,374
	Total expenses	5,055	5,276	4,569	15,277	13,843	18,418
3	Profit before exceptional items and tax	1,532	1,948	1,436	5,204	4,764	6,213
4	Exceptional items Impact of Labour Codes (See note viii)	301	-	-	301	-	-
5	Profit before tax	1,231	1,948	1,436	4,903	4,764	6,213
6	Tax expense						
	(a) Current tax	375	449	374	1,233	1,253	1,633
	(b) Deferred tax	(65)	42	8	(1)	22	(393)
	Total tax expense	310	491	382	1,232	1,275	1,240
7	Profit for the period (A)	921	1,457	1,054	3,671	3,489	4,973
8	Other comprehensive income/(loss) Items that will not be reclassified to profit or loss -Remeasurement of the defined benefit obligations -Income tax in relation to the items that will not be reclassified to profit or loss	4	18	-	10	(13)	(48)
		(1)	(5)	(1)	(3)	2	12
	Total other comprehensive income/(loss) (B)	3	13	(1)	7	(11)	(36)
9	Total comprehensive income (A+B)	924	1,470	1,053	3,678	3,478	4,937
10	Paid-up equity share capital (Face value of INR 10 per share)	1,676	838	836	1,676	836	836
11	Other equity						20,506
12	Earnings per share (INR) (Face value of INR 10 per share) (not annualised for the quarters) (See note vii)						
	- Basic	5.52	8.73	6.33	22.00	20.95	29.85
	- Diluted	5.51	8.72	6.31	21.96	20.91	29.81

Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended 31 December, 2025 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34. "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. During the nine months ended 31 December 2025, the Company has issued 183,775 equity shares of face value of INR 10 each, to "Dr. Lal PathLabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- iv. The Board of Directors of the Company have approved third interim dividend of INR 3.5 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2026.

The Board of Directors of the Company had approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 and this was paid on 17 November, 2025.

The Board of Directors of the Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 and this was paid on 14 August, 2025.

The Board of Directors of the Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025.

- v. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024.
- vi. The Board of the Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis.


The said distribution of business undertaking has been accounted for using the pooling of interests method in accordance with Appendix C of Ind AS 103 'Business combinations of entities under common control'. Accordingly, the comparative financial information for the previous periods have been restated to give effect of the consummation of business undertaking from beginning of the period disclosed and all assets, liabilities and reserves of SDIPL together with intangible assets – long term service agreements and related deferred tax liability has been recognised in the Standalone Financial Statement.

The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year end 31 March, 2025.

Accordingly, the results for the quarter and period ended 31 December, 2025, have been restated to give effect of the liquidation.

- vii. The shareholders of the Company on December 07, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed December 19, 2025 as record date. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on December 22, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter September 30, 2025 and year ended March 31, 2025 and quarter/nine months ended December 31, 2024 have been restated to give effect to the allotment of the bonus shares.
- viii. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Standalone Statement of Profit and Loss for the three months and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.
- ix. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 30 January, 2026